Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 28;23(1):1–15. doi: 10.1080/15384047.2022.2125748

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 7. — MZ1 decreases c-Myc and ANP32B expression in AML cell lines. (a) RNA-sequencing volcano plot analysis illustrates the expression changes of genes in NB4 cells between the MZ1 treatment and the control groups. Genes highlighted in red were upregulated, and those in blue were downregulated. (b) Heatmap view displayed the top downregulated genes in NB4 cells treated with 2 μM MZ1 for 32 h, including ANP32B. (c) The NB4 cell line chip-seq obtained 328 super enhancers, including super-enhancer associated gene ANP32B, ANP32A and KLF1. (d) After MZ1-treated NB4 cell down-regulated genes and NB4 cell chip-seq obtained super-enhancer associated genes were enriched, 286 common genes were obtained, including ANP32B. (e) GSEA plots displayed gene enrichment in HALLMARK_APOPTOSIS, HALLMARK_P53 and HALLMARK_TGF_BETA signaling pathways in NB4 cells treated with MZ1. (f) Western blot assay for c-Myc and ANP32B expression in the four AML cell lines. (g) Western blot analysis showed that the c-Myc and ANP32B protein levels were downregulated in NB4 and Kasumi-1 cells after treatment with different concentrations of MZ1.